Disease progression of Takayasu arteritis in two patients treated with tocilizumab

Affiliations

¹ Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA sanchez.catalina@mayo.edu.
² Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.

Comment

Catalina Sanchez-Alvarez et al. Ann Rheum Dis. 2020 Feb.

. 2020 Feb;79(2):e21.

doi: 10.1136/annrheumdis-2018-214642. Epub 2018 Dec 8.

¹ Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA sanchez.catalina@mayo.edu.
² Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA.

No abstract available

Keywords: Takayasu Arteritis; autoimmune diseases; inflammation; systemic vasculitis.

Conflict of interest statement

Conflict of interest: None declared.

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N. Nakaoka Y, et al. Ann Rheum Dis. 2018 Mar;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878. Epub 2017 Nov 30. Ann Rheum Dis. 2018. PMID: 29191819 Free PMC article. Clinical Trial.